Viridian Therapeutics (NASDAQ:VRDN) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDN) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 target price on the stock.

Other equities analysts have also recently issued reports about the stock. UBS Group began coverage on shares of Viridian Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Monday, April 20th. Wells Fargo & Company dropped their price objective on shares of Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a research note on Tuesday, March 31st. Wedbush dropped their price objective on shares of Viridian Therapeutics from $37.00 to $31.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Finally, Truist Financial dropped their price objective on shares of Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.07.

Viridian Therapeutics Stock Up 33.5%

VRDN stock opened at $18.77 on Tuesday. The company has a fifty day moving average price of $22.03 and a 200 day moving average price of $27.03. Viridian Therapeutics has a 12 month low of $11.76 and a 12 month high of $34.29. The company has a market cap of $1.93 billion, a price-to-earnings ratio of -5.71 and a beta of 0.82. The company has a debt-to-equity ratio of 0.08, a current ratio of 12.65 and a quick ratio of 12.65.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.16. Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.04 million. During the same quarter in the prior year, the firm earned ($0.87) EPS. Viridian Therapeutics’s revenue for the quarter was up 95.8% on a year-over-year basis. Sell-side analysts expect that Viridian Therapeutics will post -3.79 earnings per share for the current year.

Hedge Funds Weigh In On Viridian Therapeutics

Several institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its stake in shares of Viridian Therapeutics by 0.3% during the 1st quarter. Bank of New York Mellon Corp now owns 216,525 shares of the company’s stock worth $4,235,000 after purchasing an additional 659 shares during the period. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Viridian Therapeutics during the 1st quarter worth $752,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. grew its stake in shares of Viridian Therapeutics by 10.8% during the 1st quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 69,530 shares of the company’s stock worth $1,360,000 after purchasing an additional 6,801 shares during the period. Strs Ohio acquired a new position in shares of Viridian Therapeutics during the 1st quarter worth $417,000. Finally, SG Americas Securities LLC grew its stake in shares of Viridian Therapeutics by 81.5% during the 1st quarter. SG Americas Securities LLC now owns 60,044 shares of the company’s stock worth $1,174,000 after purchasing an additional 26,956 shares during the period.

Key Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Positive Phase 3 topline: Viridian said its REVEAL‑2 Phase 3 trial of elegrobart in chronic thyroid eye disease met its primary endpoint and showed benefits for chronic patients, a clear clinical validation that supports regulatory and commercial prospects. Viridian eye disease drug benefits chronic patients in late-stage trial
• Positive Sentiment: PDUFA / launch readiness: Management reiterated it is “launch ready” ahead of a PDUFA target date for its TED franchise, materially raising the probability of near‑term commercialization and revenue upside if approved. PDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 Results
• Positive Sentiment: Q1 results beat expectations: Viridian reported Q1 EPS of ($0.90), beating consensus (‑$1.06) and showing revenue growth (≈95.8% y/y, modest absolute dollars). The smaller‑than‑feared loss helped calm near‑term earnings anxiety. Viridian Therapeutics Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Trading halt / news flow: Shares were temporarily halted for “News Pending” ahead of these announcements, which amplified price moves when the results and corporate updates released. (This is a timing/market microstructure note rather than a fundamental change.)
• Negative Sentiment: Planned $250M+ concurrent offering: Viridian filed underwritten offerings for $150M of convertible senior notes plus $100M of common stock and related preferred — a material capital raise that could dilute existing shareholders and cap near‑term upside despite strengthening fundamentals. Viridian Announces Proposed Concurrent Public Offerings

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.